Xyall is a global innovator in molecular pathology.
Xyall has raised $9.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2026.
Xyall's investors include Capricorn Partners, Netherlands Enterprise Agency, Brabant Development, BOM Brabant Ventures, Sioux High Tech Software Ltd..
Xyall is headquartered in Eindhoven, The Netherlands.
Xyall is a global innovator in molecular pathology.
Xyall is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Xyall — Funding & Investors." VCBacked, February 11, 2026, https://www.vcbacked.co/company/xyall. Accessed September 30, 2026.
VCBacked. (2026). Xyall — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/xyall
{{cite web |title=Xyall — Funding & Investors |url=https://www.vcbacked.co/company/xyall |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated